RTA 408 Capsules in Patients With Melanoma - REVEAL
Public ClinicalTrials.gov record NCT02259231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Study identification
- NCT ID
- NCT02259231
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Interventions
- Omaveloxolone Capsules (2.5 mg/capsule) Drug
- Ipilimumab (3 mg/kg) Drug
- Nivolumab (240 mg) Drug
- Omaveloxolone Capsules (10 mg/capsule) Drug
- Omaveloxolone Capsules (50 mg/capsule) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2014
- Primary completion
- May 8, 2018
- Completion
- Jul 22, 2018
- Last update posted
- Jun 3, 2025
2014 – 2018
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center | Mobile | Alabama | 36608 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| University of Colorado Cancer Center, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Christiana Hospital Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| Goergetown-Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Atlantic Melanoma Center | Morristown | New Jersey | 07960 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02259231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2025 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02259231 live on ClinicalTrials.gov.